Nascent Biotech Founder, Dr. Mark Glassy, Will Present at the Clinical Operation in Oncology Trials Meeting, in San Diego in February

SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will be presenting on “Navigating the Unique Challenges Presented in Immune Oncology trials” in San Diego on February 12th. The meeting will be attended by influential leaders in the Pharmaceutical and Investment community. 

Nascent CEO Sean Carrick stated, “As we begin our clinical trial on Pritumumab we are pleased Dr. Glassy will be presenting on this important challenge that we are embarking on and share with the industry to help other Companies navigate the Clinical trial maze.”

Founder Mark Glassy added, “I am looking forward to presenting this important topic to the attending influencers in both the Pharmaceutical and Investment community at this conference. Sharing of information with our industry is an important part of advancing the antibodies that will impact the many people suffering from disease.”

About Nascent Biotech, Inc.

Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials.  Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995.  Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.  Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President |CEO
772.713.0541
[email protected]
www.nascentbiotech.com